AviadoBio and Astellas agree on a $2.18 billion deal to develop a gene therapy for frontotemporal dementia.

AviadoBio, a New Zealand gene therapy company, has reached a potential $2.18 billion deal with Japanese firm Astellas to develop a treatment for frontotemporal dementia (FTD). The therapy, AVB-101, aims to halt the progression of FTD, which often leads to death within three to 13 years of diagnosis. AviadoBio will receive $30 million upfront to continue human clinical trials, with promising results already seen in earlier studies.

November 23, 2024
3 Articles